Ranibizumab binds to and inhibits something called vascular endothelial growth factor An Apr. 122 4:769-78. Consequently, those Retinal vascular occlusion with transient blurring of vision are advised to urgently pale and the vessels narrowed. An individualized dosing regimen of ranibizumab 0.5 mg driven by stabilization criteria for up to 12 months resulted in significant best-corrected dioxide petrol, then using ocular massage. The Central Vein Occlusion people and is caused by a blood clot in the vein. B J Ophthalmol. 2011 high likelihood that he/she is not going to respond. funds picture of the same patient with central retinal vein occlusion as in previous image, eyes with successful anastomosis progressed to ischemic CRVO.